Fuel Cell Bus Trials on the BRT Hikoboshi Line
Fuel Cell Bus Trials on the BRT Hikoboshi Line

TOKYO, Feb 8, 2023 – (JCN Newswire via SEAPRWire.com) – Fukuoka Prefecture, Commercial Japan Partnership Technologies Corporation (CJPT), and Kyushu Railway Company (JR Kyushu) have entered an agreement to conduct trials of a small fuel cell electric bus (FC bus) that runs on hydrogen, an environmentally-friendly next-generation energy source, on the BRT Hikoboshi Line (officially... » read more

APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report

SYDNEY, Sep 2, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled “Evolution of Clinical Trials in the Asia Pacific Region”. The report was prepared by GlobalData and confirms that “the Asia-Pacific (APAC) region was the largest contributor... » read more

Zhaoke Ophthalmology Announces 2022 Interim Results
Zhaoke Ophthalmology Announces 2022 Interim Results

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, today announced its interim results for the six months ended 30 June... » read more

Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery
Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

LAUSANNE, Switzerland, Jun 29, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, today announced that the first patient has been enrolled in its Phase 3 OPTIMIZE (Once-daily Post ocular surgery Treatment for InflaMmation and paIn to... » read more

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

HONG KONG, Jun 15, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, today announced that, the first healthy subject... » read more

Novotech’s APAC and USA Leadership Teams at BIO 2022
Novotech’s APAC and USA Leadership Teams at BIO 2022

SAN DIEGO, CA, Jun 14, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, will have key executives from APAC and the US attend BIO 2022 for meetings with biotechs considering the Asia-Pacific region to expedite their clinical trials. #4907... » read more

Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan

TOKYO, May 10, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin (development code: E0302) for amyotrophic lateral sclerosis (ALS) in Japan, based on a favorable clinical results of the JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for... » read more

Essex Bio-Technology Announces 2021 Financial Results
Essex Bio-Technology Announces 2021 Financial Results

HONG KONG, Mar 22, 2022 – (ACN Newswire via SEAPRWire.com) – Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021. Highlights— The group’s turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million; — Sales coverage increased to around 10,500... » read more

Fujitsu Leverages World’s Fastest Supercomputer and AI Tech in Joint Field Trial for Safe and Efficient Tsunami Evacuations in Kawasaki City
Fujitsu Leverages World’s Fastest Supercomputer and AI Tech in Joint Field Trial for Safe and Efficient Tsunami Evacuations in Kawasaki City

TOKYO, Mar 3, 2022 – (JCN Newswire via SEAPRWire.com) – The International Research Institute of Disaster Science (IRIDeS) at Tohoku University, the Earthquake Research Institute at the University of Tokyo, Fujitsu, and the City of Kawasaki(1) today announced plans to conduct a field trial of AI that is constructed on the world’s fastest supercomputer, Japan’s... » read more

Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report
Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report

SYDNEY, Feb 9, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10 CRO in the 2021 CenterWatch Global Site Relationship Benchmark Survey. Report available here. https://novotech-cro.com/news/novotech-recognized-top-10-cro-centerwatch-site-relationship-benchmarking-report CenterWatch, established in 1994, is a global benchmarking authority for the clinical trials sector. The benchmarking... » read more

B-cell lymphoma clinical trials now open on the TrialWire Platform
B-cell lymphoma clinical trials now open on the TrialWire Platform

ADELAIDE, AUS, Jan 5, 2022 – (ACN Newswire via SEAPRWire.com) – TrialWire(TM) is pleased to announce new B-cell lymphoma clinical studies are now available on the TrialWire Platform. More than 6 million people have used TrialWire over the past few years to find clinical trials that are right for them at clinics and specialist centers... » read more

Autism clinical trials now open on the TrialWire Platform
Autism clinical trials now open on the TrialWire Platform

ADELAIDE, AUS, Jan 5, 2022 – (ACN Newswire via SEAPRWire.com) – TrialWire(TM) is pleased to announce new Autism (ASD) clinical studies are now available on the TrialWire Platform. More than 6 million people have used TrialWire over the past few years to find clinical trials that are right for them at clinics and specialist centers... » read more

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

HONG KONG, Nov 30, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab”, or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 30 November 2021, SM03 (Suciraslimab) Phase III... » read more

Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

Strasbourg, France & Tokyo, Japan, Nov 23, 2021 – (JCN Newswire via SEAPRWire.com) – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, today announce positive preliminary immunogenicity and clinical data on... » read more

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Foster City, CA, Shanghai and Hangzhou, China, Nov 22, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for... » read more